Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- Researchers from TGen and Lundquist Institute have identified SARS-CoV-2 protein fragments in extracellular vesicles as a potential biomarker for long COVID, offering the first specific diagnostic indicator for the condition. - The study analyzed blood samples from 14 long COVID patients and found 65 distinct viral protein fragments from the virus's Pp1ab protein within extracellular vesicles, which were not detected in pre-pandemic control samples. - While promising, the biomarker showed subtle molecular signals that were not consistently detected at every blood collection time point, requiring further validation studies to determine clinical utility. - The findings add to evidence suggesting SARS-CoV-2 may persist in body tissues long after initial infection, though researchers remain uncertain whether the detected fragments represent ongoing viral replication or cellular debris.
- Researchers at The Lundquist Institute have developed VX-01, a humanized monoclonal antibody that effectively targets the CotH protein on fungal cells causing mucormycosis, a deadly infection with mortality rates approaching 60%. - The novel antibody prevents fungal invasion of blood vessels, allowing antifungal medications to reach infected tissues more effectively, potentially eliminating the need for disfiguring surgeries currently required to treat the infection. - Mucormycosis cases have steadily increased over four decades, with approximately 4,000 annual cases in the US and 200,000 in Southeast Asia, particularly affecting immunocompromised patients and those with diabetes.
